MARKET

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.80
+0.20
+2.08%
After Hours: 9.90 +0.1 +1.02% 16:08 09/27 EDT
OPEN
9.66
PREV CLOSE
9.60
HIGH
9.88
LOW
9.53
VOLUME
777.51K
TURNOVER
--
52 WEEK HIGH
19.43
52 WEEK LOW
8.90
MARKET CAP
1.42B
P/E (TTM)
-10.3550
1D
5D
1M
3M
1Y
5Y
Sangamo Thearpeutics US Patent & Trademark Office Abstract For Co.'s 'NEW CAR CONSTRUCTS COMPRISING TNFR2 DOMAINS'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=5825&p=117&f=G&l=50&d=PG01&S1=20210923.PD.&OS=PD/20210923&RS=PD/20210923
Benzinga · 4d ago
Sangamo Therapeutics 'Long-Term Follow-up of Subjects Who Were Treated With ST-920' Posted To ClinicalTrials.Gov; Study Enrolling By Invitation
https://clinicaltrials.gov/ct2/show/NCT05039866
Benzinga · 09/10 13:41
Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval
Zacks.com · 08/31 14:53
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
BRISBANE, Calif., August 31, 2021--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences:
Business Wire · 08/31 12:30
Sangamo Therapeutics (NASDAQ:SGMO) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 08/10 09:21
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 2:55pm Eastern Time.
Business Wire · 08/09 20:30
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -10.00% and -6.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 21:45
BRIEF-Sangamo Therapeutics QTRLY Loss Per Share $0.33
reuters.com · 08/05 20:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SGMO. Analyze the recent business situations of SANGAMO THERAPEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SGMO stock price target is 20.67 with a high estimate of 30.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 292
Institutional Holdings: 82.96M
% Owned: 57.08%
Shares Outstanding: 145.34M
TypeInstitutionsShares
Increased
59
3.10M
New
17
468.40K
Decreased
74
4.69M
Sold Out
21
2.04M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.24%
Pharmaceuticals & Medical Research
-0.92%
Key Executives
Non-Executive Chairman/Independent Director
H. Stewart Parker
President/Chief Executive Officer/Director
Alexander Macrae
Chief Financial Officer/Senior Vice President
Prathyusha Duraibabu
Executive Vice President
D. Mark McClung
Executive Vice President
R. Andrew Ramelmeier
Senior Vice President/Chief Scientific Officer
Jason Fontenot
Senior Vice President
Robert Schott
Independent Director
Robert Carey
Independent Director
Kenneth Hillan
Independent Director
John Markels
Independent Director
James Meyers
Independent Director
Saira Ramasastry
Independent Director
Karen Smith
Independent Director
Joseph Zakrzewski
No Data
  • All
  • Financials
  • Insiders
More
About SGMO
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Webull offers kinds of Sangamo Therapeutics Inc stock information, including NASDAQ:SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.